Market Trends of Human Respiratory Syncytial Virus Treatment Industry
Parenteral Segment is Expected to Witness a Healthy Growth in the Market Over the Forecast Period
The parenteral segment is expected to witness growth in the studied market due to the increase in the development of vaccines against RSV and the rise in the prevalence of RSV diseases across the globe. For instance, as per the article published in December 2022 in Nature journal, researchers had developed a vaccine containing RSV particles that were chemically inactivated so that the virus couldn't replicate. Rather than attempting to create a vaccine from an inactivated virus, researchers aimed to create a protein-based vaccination in which an isolated component of the virus, such as a surface protein, is used to stimulate a protective immune response. Hence, such an increase in research development of the parenteral route of RSV treatment is expected to boost segment growth.
Moreover, many of the key players receiving the approvals and different designations for their clinical assets for RSV treatment are expected to drive the market growth. For instance, in March 2022, a Pfizer vaccine candidate received Breakthrough Therapy Designation from the FDA for the prevention of RSV-associated lower respiratory tract disease in infants up to six months of age by active immunization of pregnant women. Further, in April 2022, ModernaTX, Inc. sponsored a clinical study to evaluate the impact of co-administered influenza vaccine on the immune response to RSV-A and to evaluate the impact of the co-administered RSV vaccine on the immune response to influenza.
Hence, a rise in demand for the parenteral route of administration in RSV infection and an increase in pipeline assets by the key players are expected to drive the growth of the studied segment over the forecast period.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is expected to hold a significant market share in the studied market due to the increase in RSV infection, rise in research and development, presence of key players, and increase in healthcare expenditure in the region. For instance, in November 2022, GSK Canada filed a New Drug Submission (NDS) to Health Canada for its respiratory syncytial virus (RSV) older adult vaccine candidate. GSK'S RSV older adult vaccine candidate has the potential to be the first vaccine available to help protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection.
Similarly, In November 2022, Pfizer publicized the positive top-line data of phase 3 global maternal immunization trial for its bivalent respiratory syncytial virus (RSV) vaccine candidate. Vaccine efficacy of 81.8% was observed against severe medically attended lower respiratory tract illness due to RSV in infants from birth through the first 90 days of life with high efficacy of 69.4% demonstrated through the first six months of life. Hence, such clinical studies by the major players are expected to increase the market growth of RSV therapies in the region. Moreover, as per the November 2022 CDC health advisory and media briefing, the incidence of respiratory syncytial virus (RSV) is increasing in 8 out of 10 public health regions in the U.S. (all except the Southeast and South-Central parts of the country). At that time, some regions were already nearing levels typically observed during the virus's seasonal peak months of December or January. Hence, such a rise in the prevalence of RSV in the studied region is expected to drive market growth over the forecast period.
Hence, due to the rise in RSV infection and an increase in pipeline assets by the key players, North America is expected to hold a significant market share over the forecast period.
